Corbus Pharmaceuticals Holdings, Inc.
CRBP
$7.70
$0.141.85%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 76.41% | 117.54% | 98.84% | 92.77% | 78.84% |
| Gross Profit | -76.41% | -117.54% | -98.84% | -92.77% | -78.84% |
| SG&A Expenses | -7.18% | -7.78% | -2.10% | 18.28% | 20.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 52.60% | 75.10% | 64.32% | 66.75% | 57.40% |
| Operating Income | -52.60% | -75.10% | -64.32% | -66.75% | -57.40% |
| Income Before Tax | -68.09% | -95.32% | -74.45% | -65.72% | -48.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -68.09% | -95.32% | -74.45% | -65.72% | -48.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -68.09% | -95.32% | -74.45% | -65.72% | -48.97% |
| EBIT | -52.60% | -75.10% | -64.32% | -66.75% | -57.40% |
| EBITDA | -53.61% | -76.75% | -65.79% | -68.22% | -58.61% |
| EPS Basic | -37.61% | -63.14% | -17.43% | 18.15% | 39.37% |
| Normalized Basic EPS | -29.14% | -51.39% | -24.42% | 12.51% | 34.66% |
| EPS Diluted | -37.61% | -63.14% | -17.43% | 18.15% | 39.37% |
| Normalized Diluted EPS | -29.14% | -51.39% | -24.42% | 12.51% | 34.66% |
| Average Basic Shares Outstanding | 25.90% | 22.21% | 36.67% | 72.40% | 121.36% |
| Average Diluted Shares Outstanding | 25.90% | 22.21% | 36.67% | 72.40% | 121.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |